Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells

[1]  D. Bidwell,et al.  Formation , 2006, Revue Francophone d'Orthoptie.

[2]  P. Cole,et al.  Inhibiting the coregulator CoREST impairs Foxp3+ Treg function and promotes antitumor immunity. , 2020, The Journal of clinical investigation.

[3]  Michael R. Green,et al.  Mechanistic basis and efficacy of targeting β-catenin-TCF7L2-JMJD6-MYC axis to overcome resistance to BET inhibitors. , 2019, Blood.

[4]  Charles C. Bell,et al.  Principles and mechanisms of non-genetic resistance in cancer , 2019, British Journal of Cancer.

[5]  Guochao Liao,et al.  LSD1/KDM1A inhibitors in clinical trials: advances and prospects , 2019, Journal of Hematology & Oncology.

[6]  T. Somervaille,et al.  Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia , 2019, Leukemia.

[7]  G. Natsoulis,et al.  A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis , 2019, Blood.

[8]  M. Kawahara,et al.  LSD1-mediated repression of GFI1 super-enhancer plays an essential role in erythroleukemia , 2019, Leukemia.

[9]  Mariella G. Filbin,et al.  Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG. , 2019, Cancer cell.

[10]  B. A. van der Reijden,et al.  Targeting the GFI1/1B—CoREST Complex in Acute Myeloid Leukemia , 2019, Front. Oncol..

[11]  E. Wang,et al.  What potential is there for LSD1 inhibitors to reach approval for AML? , 2019, Expert opinion on emerging drugs.

[12]  G. Schneider,et al.  HDAC3 Activity is Essential for Human Leukemic Cell Growth and the Expression of β-catenin, MYC, and WT1 , 2019, Cancers.

[13]  T. Möröy,et al.  Role of GFI1 in Epigenetic Regulation of MDS and AML Pathogenesis: Mechanisms and Therapeutic Implications , 2019, Front. Oncol..

[14]  Michael R. Green,et al.  RUNX1 targeted therapy for AML expressing somatic or germline mutation in RUNX1. , 2019, Blood.

[15]  Francine E. Garrett-Bakelman,et al.  Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML. , 2019, Cancer discovery.

[16]  S. Dawson,et al.  Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia , 2019, Nature Communications.

[17]  Eugene E. Kwan,et al.  CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML , 2019, Nature Chemical Biology.

[18]  S. Amente,et al.  Expanding the Role of the Histone Lysine-Specific Demethylase LSD1 in Cancer , 2019, Cancers.

[19]  Y. Inoue,et al.  Lysine-Specific Demethylase 1 (LSD1/KDM1A) Is a Novel Target Gene of c-Myc. , 2019, Biological & pharmaceutical bulletin.

[20]  J. Schütte,et al.  LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML , 2019, Leukemia.

[21]  K. Rajapakshe,et al.  Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells , 2019, Blood Cancer Journal.

[22]  P. Qiu,et al.  Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML , 2018, Leukemia.

[23]  Nghi Nguyen,et al.  Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth , 2018, Nature.

[24]  Karen E Gascoigne,et al.  Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation. , 2018, Cell reports.

[25]  Daniela Magliulo,et al.  Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid Leukemia , 2018, Front. Oncol..

[26]  T. Somervaille,et al.  LSD1 inhibitors disrupt the GFI1 transcription repressor complex , 2018, Molecular & cellular oncology.

[27]  G. Freeman,et al.  LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade , 2018, Cell.

[28]  S. Armstrong,et al.  LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML. , 2018, Blood.

[29]  Markus G. Manz,et al.  Molecular Minimal Residual Disease in Acute Myeloid Leukemia , 2018, The New England journal of medicine.

[30]  Yaoyong Li,et al.  Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia , 2018, Cell reports.

[31]  James E. Bradner,et al.  The dTAG system for immediate and target-specific protein degradation , 2018, Nature Chemical Biology.

[32]  A. Melnick,et al.  ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia. , 2018, Cancer cell.

[33]  S. Manalis,et al.  Targeting minimal residual disease: a path to cure? , 2018, Nature Reviews Cancer.

[34]  Steven P. Angus,et al.  Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer. , 2018, Annual review of pharmacology and toxicology.

[35]  Yun Song,et al.  Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors , 2018, Nature Communications.

[36]  Darren L. Smith,et al.  Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist. , 2017, Cancer discovery.

[37]  Sydney M. Shaffer,et al.  Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance , 2017, Nature.

[38]  R. Sood,et al.  Role of RUNX1 in hematological malignancies. , 2017, Blood.

[39]  R. Majeti,et al.  Biology and relevance of human acute myeloid leukemia stem cells. , 2017, Blood.

[40]  R. Young,et al.  Transcriptional Addiction in Cancer , 2017, Cell.

[41]  P. Qiu,et al.  BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells , 2016, Leukemia.

[42]  Claude Preudhomme,et al.  A 17-gene stemness score for rapid determination of risk in acute leukaemia , 2016, Nature.

[43]  R. Hara,et al.  A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells , 2016, Molecular Cancer Therapeutics.

[44]  Bradley E. Bernstein,et al.  Single-molecule decoding of combinatorially modified nucleosomes , 2016, Science.

[45]  F. Robert,et al.  GFI1 as a novel prognostic and therapeutic factor for AML/MDS , 2016, Leukemia.

[46]  S. Franklin,et al.  GFI1 functions in transcriptional control and cell fate determination require SNAG domain methylation to recruit LSD1. , 2016, The Biochemical journal.

[47]  Crispin J. Miller,et al.  GFI1 proteins orchestrate the emergence of haematopoietic stem cells through recruitment of LSD1 , 2015, Nature Cell Biology.

[48]  T. Möröy,et al.  From cytopenia to leukemia: the role of Gfi1 and Gfi1b in blood formation. , 2015, Blood.

[49]  A. Verma,et al.  Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia , 2015, Nature Medicine.

[50]  J. Kinney,et al.  Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains , 2015, Nature Biotechnology.

[51]  Charles Y. Lin,et al.  Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. , 2015, Molecular cell.

[52]  A. Shilatifard,et al.  Chromatin signatures of cancer , 2015, Genes & development.

[53]  J. Qi,et al.  BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD , 2014, Molecular Cancer Therapeutics.

[54]  K. Bhalla,et al.  Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells , 2014, Leukemia.

[55]  J. Qi,et al.  Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells , 2014, Molecular Cancer Therapeutics.

[56]  Jae-seok Roe,et al.  C/EBPα: critical at the origin of leukemic transformation , 2014, The Journal of experimental medicine.

[57]  Li Jianguo,et al.  Advances and prospects , 2014 .

[58]  Mark Cockerill,et al.  CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1. , 2013, Analytical biochemistry.

[59]  S. Amente,et al.  The histone LSD1 demethylase in stemness and cancer transcription programs. , 2013, Biochimica et biophysica acta.

[60]  Robert A Copeland,et al.  Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. , 2013, Blood.

[61]  Martin Dugas,et al.  Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia , 2012, Nature Medicine.

[62]  Z. Otwinowski,et al.  Structural basis for CoREST-dependent demethylation of nucleosomes by the human LSD1 histone demethylase. , 2006, Molecular cell.

[63]  André Hoelz,et al.  Crystal structure and mechanism of human lysine-specific demethylase-1 , 2006, Nature Structural &Molecular Biology.

[64]  F. Lan,et al.  Regulation of LSD1 histone demethylase activity by its associated factors. , 2005, Molecular cell.